ADMA Biologics: Court Sets August 10 Deadline for Lead Plaintiff in Securities Class Action
Investors who purchased ADMA Biologics securities between August 2024 and March 2026 have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit. The suit alleges violations of federal securities laws.
Investors who bought or acquired ADMA Biologics, Inc. (NasdaqGM: ADMA) securities between August 9, 2024, and March 25, 2026, must file lead plaintiff applications by August 10, 2026, in a class action lawsuit. The action is currently pending in the U.S. District Court for the District of New Jersey.
The lawsuit accuses ADMA and certain of its executives of failing to disclose material information during the class period, thereby violating federal securities laws. Investors who believe they have suffered losses exceeding $100,000 are encouraged to seek legal counsel.
Allegations in the complaint include that the company engaged in an undisclosed related party transaction, used improper sales tactics to inflate revenue figures, and lacked adequate internal controls. These alleged misrepresentations and omissions are said to have made statements about the company's business and prospects misleading.
The case is titled Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-04793. Lawyers are available to discuss potential legal options for affected investors.